Protalex Inc

Protalex — Investor Presentation (January 2015)

17 slides from Protalex's investor presentation, Jan 20, 2015

  1. Slide 1: Protalex PRTX January 2015

    PRTX PROTALE January, 2015

  2. Slide 2: Forward-Looking Statement

    Protalex, Inc. Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The Company ’ s actual results could differ materially from those projected herein. Additional information is contained in t

  3. Slide 3: Protalex, Inc. (Ticker: PRTX)

    Protalex, Inc. Protalex, Inc. (Ticker: PRTX) ▪ Rheumatoid Arthritis (>$18B) ▪ ITP (~$1B) ▪ Other Autoimmune Diseases ($Bs) 3 ▪ Experienced Management ▪ Strong Scientific Advisors ▪ Low - burn Model ▪ Funded - to - date by majority shareholder ▪ Highly - purified b acterial protein ▪ W ell - studied

  4. Slide 4: The Big Picture: A Huge Market with Unmet Needs

    Protalex, Inc. The BIG PICTURE A Huge Market with unmet needs o Today in the US, millions of individuals suffer from autoimmune diseases, like rheumatoid arthritis (RA) — the largest autoimmune market, and Immune Thrombocytopenia (ITP) — bruising and bleeding that does not easily heal. ITP is an orp

  5. Slide 5: The Most Important Unmet Need is Safety

    The M ost I mportant Unmet Need is SAFETY o Humira, Enbrel and Remicade are TNF - inhibitors o All three drugs suppress the immune system, and that has a major impact on those who take them. o The FDA requires them to carry a Black Box Warning for such problems as: o Congestive Heart Failure, Blood

  6. Slide 6: FDA Black Box Warnings: A Safer RA Drug is Needed

    Protalex, Inc. FDA Black Box Warnings A Safer RA drug is needed o Each major RA drug has over 12 different types of Serious Adverse Events o In five human clinical studies, PRTX - 100 has not had one drug related Serious Adverse Event - a Black Box Event. o To date, PRTX - 100 has shown a superior s

  7. Slide 7: Efficacy of RA Drugs

    Efficacy of RA Drugs 50% 50% 39% 0% 10% 20% 30% 40% 50% 60% Day 85 Day 113 Day 102 PRTX Enbrel MTX ACR50 Scores 0% 10% 20% 30% 40% 50% 60% 7 DAS28 < 3.2 Protalex, Inc .

  8. Slide 8: Durability of Treatment

    Protalex, Inc. Durability of Treatment Number of Treatments per Year 0 20 40 60 80 100 120 8 Number of Treatments per Year

  9. Slide 9: What Drug Should be Used? The Answer is not Easy

    What Drug Should be Used ? The Answer is not Easy  To the left is EULAR’s summary of a 20 page recommendation for the treatment path of RA  An RA drug would become the first choice to use - -  If it was a safer treatment than the current drugs or  If a Responder Screening Test for the drug exist

  10. Slide 10: Competitive Advantages to Current Biologicals

    Competitive Advantages of PRTX - 100 to Current Biologicals  No FDA Black Box - Does not suppress the immune system  Attractive safety profile allows for potential use in combination with other therapies  Potentially applicable across a broad range of autoimmune diseases  Considerably lower cost

  11. Slide 11: Immune Thrombocytopenia (ITP): A Rare and Serious Disorder

    Protalex, Inc. Immune Thrombocytopenia (ITP) A Rare and Serious Disorder  An Orphan Disease in the US and Europe  Abnormally low platelet count in the blood  Daily or Weekly treatment for life  Annual cost of treatment is about $60,000  Promacta® & Nplate® only globally approved treatments ($1B

  12. Slide 12: Protalex Milestones

    Protalex, Inc. Protalex Milestones x 2Q13 Safety data from first three cohorts of PRTX - 100 - 104 x 3Q13 Initiation of Cohort 5 extension study, to investigate monthly maintenance doses x 2Q14 Top - line results of PRTX - 100 - 104 trial x 4Q14 Filing IND for PRTX - 100 in ITP □ 1Q15 Top - line res

  13. Slide 13: Development Plans

    PRTX - 100 Development Plans 13 2012 2013 2014 2015 2016 2017 PRTX - 100 Rheumatoid Arthritis PRTX - 100 Immune Thrombocytopenia Phase 1 So. Africa PRTX - 100 - 103 Phase 1 in USA PRTX - 100 - 104 Phase 2 Phase 3 Explore Partnership Preclinical Phase 1/2 Phase 3 Protalex, Inc. 105 Continuation Study

  14. Slide 14: Protalex Key Team Members

    Protalex, Inc. Protalex Key Team Members  Arnold P Kling – President, Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies  James W Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment mana

  15. Slide 15: Patents and Intellectual Property

    Protalex, Inc. Patents and Intellectual Property  Patents (five issued in US and two in Japan) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 for RA, juvenile RA, and systemic lupus erythematosus ▪ Continuation patents expanding use were issued

  16. Slide 16: Protalex Investment Thesis Summary

    Protalex, Inc. Protalex Investment Thesis Summary  PRTX - 100 – potentially a blockbuster drug ▪ Potential treatment of diseases in both large and small markets (RA, ITP) ▪ Potentially efficacy in a number of orphan diseases ▪ Considerable cost of goods advantage over competitive drugs ▪ To date, a

  17. Slide 17: Protalex PRTX January 2015

    PRTX PROTALE January, 2015

Protalex — Investor Presentation (January 2015) on 6ix